Eli Lilly Introduces R&D Facility

In Boston’s Seaport neighbourhood, US, Eli Lilly and Company has established the Lilly Seaport Innovation Centre (LSC), a centre for research and development (R&D).

The facility will further the business’s research on RNA- and DNA-based treatments and identify novel targets for diabetes, obesity, and cardiovascular diseases. The twelve-story structure, which is 346,000 square feet in size, houses offices and lab space.

Alexandria Real Estate Equities is the developer and operator of the hub, which will house the first East Coast Lilly Gateway Labs with the goal of accelerating the discovery of novel medicines and improving teamwork. It can hold 500 scientists and researchers from Lilly.

Lilly Research Laboratories chief scientific officer and president, and Lilly immunology president Daniel Skovronsky commented: “The opening of LSC expands upon Lilly’s long-standing presence in the Boston area.’’

He continued: “We are committed to being supportive neighbors in this hub of discovery and innovation, further collaborating with leading institutions and new talent to continue delivering transformative medicines for the people who need them most.”